Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
NCT ID NCT04510636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining pembrolizumab (Keytruda) with bendamustine (Treanda) is safe and effective for people with Hodgkin lymphoma that has come back or is no longer responding to standard treatments. About 40 adults will receive the drug combination, and researchers will measure how many achieve a complete or partial response using PET/CT scans. The goal is to see if this two-drug approach can shrink or eliminate cancer in this difficult-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and bendamustine (Treanda)
What this could lead to
If successful, this combination could offer a new treatment option for people with Hodgkin lymphoma that has returned or stopped responding to standard therapy.
What could go wrong
This is a small, early-phase study (40 participants) without a comparison group, so results may not be definitive. Side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
Contact